A practical reference on MOD GRF(1-29): what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-11. Anything still debated is marked as such rather than presented as settled.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
| Property | Value | Notes |
|---|---|---|
| Duration with linker | Several days | Reported in early human work |
| Duration without linker | Tens of minutes | Short plasma residence |
| Albumin attachment site | Cysteine-34 | Covalent maleimide reaction |
| Primary receptor | Pituitary GHRH receptor | Stimulates growth hormone release |
| Downstream marker | Insulin-like growth factor 1 | Indirect measure of activity |
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Superoxide (O−2) is produced by reduction of O2. Several grams are produced per day in the human body within the mitochondria. O2 + e− → O−2 Competing with its formation, superoxide is destroyed by the action of superoxide dismutases, enzymes that catalyze its disproportionation:
This is analogous to moving a large object: you move one end first, then the other. Chemical modification experiments provided evidence of this hybrid model, in which tRNAs can sample a hybrid state of binding during the elongation phase (pre-translocation step). In these hybrid states of binding, acceptor and anti-codon ends of tRNA are in different sites (A, P and E). Using chemical probing methods, a set of phylogenetically conserved bases in ribosomal RNA where the tRNA binds has been examined, and is suggested to be directly involved in the binding of tRNA to the prokaryotic ribosome. Correlation of such site-specific protected bases in rRNA and occupancy of the A, P and E sites has allowed diagnostic assays of these bases to study the location of tRNA in any given state of the translational cycle. Authors proposed a hybrid model in which higher affinity of the deactivated tRNA and peptide tRNA for the E and P sites of the 50S subunit, thermodynamically favours P/P to P/E and A/A to A/P transitions, which were further demonstrated through cryo-EM experiments. Also, single molecule FRET studies have detected fluctuations in the positions of tRNAs, leading to the conclusion that the classical (A/A-P/P) and hybrid states (A/P-P/E) of the tRNAs are certainly in dynamic equilibrium. Prior to peptide bond formation, an aminoacyl-tRNA is bound in the A-site, a peptidyl-tRNA is bound in the P-site, and a deacylated tRNA (ready to exit from the ribosome) is bound to the E-site.
The Newcomb Cleveland Prize of the American Association for the Advancement of Science (AAAS) is annually awarded to author(s) of outstanding scientific paper published in the Research Articles or Reports sections of Science. Established in 1923, funded by Newcomb Cleveland who remained anonymous until his death in 1951, and for this period it was known as the AAAS Thousand Dollar Prize. "The prize was inspired by Mr. Cleveland's belief that it was the scientist who counted and who needed the encouragement an unexpected monetary award could give." The present rules were instituted in 1975, previously it had gone to the author(s) of noteworthy papers, representing an outstanding contribution to science, presented in a regular session, sectional or societal, during the AAAS Annual Meeting. It is now sponsored by the Fodor Family Trust and includes a prize of $25,000. The prize's current sponsorship has a notable connection to a past winner: Stephen P. A. Fodor, founder of Affymetrix, received the prize in 1990 for a paper introducing microarray technology. Affymetrix added its support to the prize in 2003, more than doubling its monetary value at the time. Winners receive a bronze medal, a share of the prize money, and reimbursement for travel to the AAAS Annual Meeting. Final selection is determined by a panel of distinguished scientists appointed by the editor-in-chief of Science. The annual contest period runs from the first issue of June through the last issue of the following May. No prize was awarded in 1942–1945, 1948, 1973, 1975, or 1976.
Sources: en.wikipedia.org
The deportees were released on 19 December and allowed to travel to Cairo and then, with Jamal Husseini, to Beirut where a new Arab Higher Committee (or Higher National Committee) was established. Amin al-Husayni was not a member of the Arab delegation but the delegation was clearly acting under his direction. The London Conference commenced on 7 February 1939, but the Arab delegation refused to sit in the same room with the Jewish delegation present, and the conference broke up in March with no success. In May 1939, the British government presented its 1939 White Paper which was rejected by both sides. The White Paper had, in effect, repudiated the Balfour Declaration. According to Benny Morris, Amin al-Husayni "astonished" the other members of the Arab Higher Committee by turning down the White Paper. Al-Husayni turned the advantageous proposal down because "it did not place him at the helm of the future Palestinian state." The deportees were not allowed to return to Palestine until 1941. Amin Al-Husayni spent the war years in occupied Europe, actively collaborating with the Nazi leadership. Amin and Jamal al-Husayni were involved in the 1941 pro-Nazi Rashidi revolt in Iraq. Amin again evaded capture by Britain but Jamal was captured in 1941 and interned in Southern Rhodesia, where he was held until November 1945 when he was allowed to move to Cairo. Husayn al-Khalidi returned to Palestine in 1943. Jamal al-Husayni returned to British Palestine in February 1946 as an official of the new Arab Higher Committee, by then recognised by the Mandate administration.
=== Thioredoxin reductase === Thioredoxin reductase uses a cysteine-selenocysteine pair to reduce the disulfide in thioredoxin. The selenocysteine is arranged in an unusual Sec-His-Glu catalytic triad, which tunes its pKa.
Induction chemotherapy is the first line treatment of cancer with a chemotherapeutic drug. This type of chemotherapy is used for curative intent. Combined modality chemotherapy is the use of drugs with other cancer treatments, such as surgery, radiation therapy, or hyperthermia therapy. Consolidation chemotherapy is given after remission in order to prolong the overall disease-free time and improve overall survival. The drug that is administered is the same as the drug that achieved remission. Intensification chemotherapy is identical to consolidation chemotherapy but a different drug than the induction chemotherapy is used. Combination chemotherapy involves treating a person with a number of different drugs simultaneously. The drugs differ in their mechanism and side-effects. The biggest advantage is minimising the chances of resistance developing to any one agent. Also, the drugs can often be used at lower doses, reducing toxicity. Neoadjuvant chemotherapy is given prior to a local treatment such as surgery, and is designed to shrink the primary tumor. It is also given for cancers with a high risk of micrometastatic disease. Adjuvant chemotherapy is given after a local treatment (radiotherapy or surgery). It can be used when there is little evidence of cancer present, but there is risk of recurrence. It is also useful in killing any cancerous cells that have spread to other parts of the body. These micrometastases can be treated with adjuvant chemotherapy and can reduce relapse rates caused by these disseminated cells.
Sources: en.wikipedia.org
Cryopreservation for embryos is used for embryo storage, e.g., when IVF has resulted in more embryos than is currently needed. One pregnancy and resulting healthy birth has been reported from an embryo stored for 27 years, after the successful pregnancy of an embryo from the same batch three years earlier. Many studies have evaluated the children born from frozen embryos, or "frosties". The result has been uniformly positive with no increase in birth defects or development abnormalities. A study of more than 11,000 cryopreserved human embryos showed no significant effect of storage time on post-thaw survival for IVF or oocyte donation cycles, or for embryos frozen at the pronuclear or cleavage stages. Additionally, the duration of storage did not have any significant effect on clinical pregnancy, miscarriage, implantation, or live birth rate, whether from IVF or oocyte donation cycles. Rather, oocyte age, survival proportion, and number of transferred embryos are predictors of pregnancy outcome.
== Political impact == In Britain the Liberal Party objected to, and later opposed, the Boer War. Later, Jameson became Prime Minister of the Cape Colony (1904–08) and one of the founders of the Union of South Africa. He was made a baronet in 1911 and returned to England in 1912. On his death in 1917, he was buried next to Cecil Rhodes and the 34 BSAC soldiers of the Shangani Patrol (killed in 1893 in the First Matabele War) in the Matobos Hills, near Bulawayo.
== Similar approaches == The idea of using protein design to accomplish the same goals as DNA origami has surfaced as well. Researchers at the National Institute of Chemistry in Slovenia are working on using rational design of protein folding to create structures much like those seen with DNA origami. The main focus of current research in protein folding design is in the drug delivery field, using antibodies attached to proteins as a way to create a targeted vehicle.
==== Multi-phase model ==== LNAPLs and DNAPLs can exist in multiple different phases simultaneously upon entering the subsurface environment. The composition of NAPLs is typically described using a multi-phase model that depends on a variety of complex and interrelated parameters, including, but not limited to, viscosity, solubility, and volatility; the possible phases of NAPL include gaseous, solid, aqueous, and immiscible hydrocarbon. The liquid phase of NAPLs is characterized by a physical dividing surface that separates it from the liquid phase of water, indicating immiscibility due to NAPLs' organic structure. That said, some chemical compounds within the NAPL are capable of solubilizing into water, meaning that two liquid phases of NAPL (immiscible hydrocarbon and aqueous solute) can exist simultaneously. The gaseous phase of NAPLs is also responsible for the contamination of groundwater and soil; therefore, the distribution of NAPLs between its various phases is important to quantify in order to assess the extent of contamination and to determine appropriate remediation strategies.
Sources: en.wikipedia.org
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.
The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.
Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.